Hetero Labs Limited — Dolutegravir Exporter Profile
Indian Pharmaceutical Exporter · #2 for Dolutegravir · $35.5M export value · DGFT Verified
Hetero Labs Limited is the #2 Indian exporter of Dolutegravir with $35.5M in export value and 709 verified shipments. Hetero Labs Limited holds a 0.8% market share in Dolutegravir exports across 94 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.
Hetero Labs Limited — Dolutegravir Export Profile: Buyers & Destinations
Where Does Hetero Labs Limited Export Dolutegravir?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NIGERIA | $3.3M | 68 | 12.9% |
| SOUTH AFRICA | $3.0M | 62 | 12.0% |
| KENYA | $2.5M | 51 | 9.9% |
| PHILIPPINES | $1.8M | 38 | 7.1% |
| VIETNAM | $1.3M | 27 | 5.2% |
| TANZANIA | $1.2M | 24 | 4.8% |
| MOZAMBIQUE | $1.1M | 23 | 4.6% |
| KAZAKISTAN | $916.0K | 26 | 3.6% |
| PERU | $847.9K | 18 | 3.4% |
| NETHERLANDS | $785.8K | 60 | 3.1% |
Hetero Labs Limited exports Dolutegravir to 102 countries. The largest destination is NIGERIA accounting for 12.9% of Hetero Labs Limited's Dolutegravir shipments, followed by SOUTH AFRICA (12.0%) and KENYA (9.9%). These destinations reflect Hetero Labs Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Dolutegravir from Hetero Labs Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER OF | UNITED ARAB EMIRATES | $12.6M | 321 |
| TO THE ORDER | ZAMBIA | $2.5M | 63 |
| HOANG DUC PHARMACEUTICAL & | VIETNAM | $803.7K | 17 |
| HOANG DUC PHARMACEUTICAL & MEDICAL | VIETNAM | $500.0K | 10 |
| TO THE ORDER OF, | KAZAKISTAN | $450.0K | 9 |
| M S TO THE ORDER OFTHE MISSION DIRECTOR USAGENCY | NIGERIA | $450.0K | 9 |
| M/S | KAZAKISTAN | $441.2K | 14 |
| SEVEN PHARMA S.A.C, | PERU | $350.0K | 7 |
| XXTERXXDRUXX SOXXH AXXICAXXPTYXXLIMITEDX | SOUTH AFRICA | $300.0K | 6 |
| SEVEN PHARMA S.A.C., | PERU | $300.0K | 6 |
Hetero Labs Limited supplies Dolutegravir to 115 buyers globally. The largest buyer is TO THE ORDER OF (UNITED ARAB EMIRATES), followed by TO THE ORDER (ZAMBIA) and HOANG DUC PHARMACEUTICAL & (VIETNAM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Dolutegravir Export Value and How Much Does Hetero Labs Limited Contribute?
India exported $144.2M worth of Dolutegravir through 3,325 shipments from 104 suppliers to 145 countries, serving 592 buyers globally. Hetero Labs Limited contributes $35.5M to this total, accounting for 0.8% of India's Dolutegravir exports. Hetero Labs Limited ships Dolutegravir to 102 countries through 115 buyers.
What Is the Average Shipment Value for Hetero Labs Limited's Dolutegravir Exports?
Hetero Labs Limited's average Dolutegravir shipment value is $50.0K per consignment, based on 709 shipments totaling $35.5M. The largest destination is NIGERIA (12.9% of Hetero Labs Limited's Dolutegravir exports).
How Does Hetero Labs Limited Compare to Other Indian Dolutegravir Exporters?
Hetero Labs Limited ranks #2 among 104 Indian Dolutegravir exporters with a 0.8% market share. The top 3 exporters are CIPLA LIMITED ($47.5M), HETERO LABS LIMITED ($35.5M), EMCURE PHARMACEUTICALS LIMITED ($19.4M). Hetero Labs Limited processed 709 shipments to 94 destination countries.
What Dolutegravir Formulations Does Hetero Labs Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DOLUTEGRAVIR 50 + LAMIVUDINE 300 + TENOF | $2.0M | 59 |
| DOLUTEGRAVIR+LAMIVUDINE+TENOFOVIR DISOPRTABLET | $964.5K | 26 |
| DOLUTEGRAVIR+LAMIVUDINE+TENOFOVIR DISOPR | $761.8K | 17 |
| TELDY DOLUTEGRAVIR+LAMIVUDINE+TENOFOVIRDISOPR TABLET | $616.3K | 13 |
| LUVIGEN DOLUTEGRAVIR + LAMIVUDINE+TENOFOVIR DISOPR TABLETS GREEN CARD NO.518/VSEZ DT. 15.03.26NOS | $450.0K | 9 |
| DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR DI | $418.9K | 14 |
| DOLUTEGRAVIR+LAMIVUDINE+TENOFOVIR DISOPRTABLETS | $378.4K | 8 |
| DOLUTEGRAVIR 50+LAMIVUDINE 300+TENOFOVIR | $370.1K | 8 |
| DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR DISO. FUM.(TELDY) | $350.0K | 7 |
| DOLUTEGRAVIR+LAMIVUDINE+TENOFOVIR DISOPR50MG+300MG+300MG TABLET 30S | $335.3K | 16 |
Hetero Labs Limited exports 341 distinct Dolutegravir formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DOLUTEGRAVIR 50 + LAMIVUDINE 300 + TENOF with 59 shipments worth $2.0M. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Dolutegravir to Key Markets
What Hetero Labs Limited must comply with to export Dolutegravir to its top destination countries
Nigeria — NAFDAC
Approval Process
Drug registration under NAFDAC guidelines. WHO-type CPP from India required.
Timeline: 6–18 months
GMP & Export Requirements
WHO GMP compliance; NAFDAC conducts overseas plant inspections
Certificate of Pharmaceutical Product (CPP) from CDSCO India; NAFDAC import permit
Note: India is the largest pharma supplier to Nigeria. NAFDAC has intensified Indian site inspections.
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Hetero Labs Limited Compare to Nearest Dolutegravir Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | CIPLA LIMITED | $47.5M | 949 | 40 | $50.0K |
| 2 | HETERO LABS LIMITED ★ | $35.5M | 709 | 94 | $50.0K |
| 3 | EMCURE PHARMACEUTICALS LIMITED | $19.4M | 389 | 46 | $50.0K |
| 1 | MACLEODS PHARMACEUTICALS LTD | $16.8M | 336 | 67 | $50.0K |
Hetero Labs Limited ranks #2 among 104 Indian Dolutegravir exporters. Average shipment value of $50.0K compared to the market average of $1.4M. The closest competitors by value are CIPLA LIMITED and EMCURE PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Dolutegravir Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 610 | 18.3% |
| NHAVA SHEVA SEA (INNSA1) | 465 | 14.0% |
| JNPT/ NHAVA SHEVA SEA | 316 | 9.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 284 | 8.5% |
| JNPT | 180 | 5.4% |
| HYDERABAD ACC (INHYD4) | 164 | 4.9% |
| HYDERABAD AIR | 147 | 4.4% |
| DELHI AIR | 137 | 4.1% |
What Other Antiviral & HIV Medications Products Does Hetero Labs Limited Export?
Hetero Labs Limited also exports these antiviral & hiv medications products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Hetero Labs Limited's Dolutegravir Exports
The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.
Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.
The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.
Hetero Labs Limited — Regulatory Compliance & Quality Standards
Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.
About Hetero Labs Limited
Hetero Labs Limited exports 46 products worth $319.3M. Beyond Dolutegravir, top products include Tenofovir, Ritonavir, Acyclovir, Valacyclovir, Oseltamivir. View the complete Hetero Labs Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Dolutegravir — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Dolutegravir shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 709 individual customs records matching Hetero Labs Limited exporting Dolutegravir, covering 341 formulations to 102 countries via 115 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 145+ countries, 592+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Dolutegravir Export Data from Hetero Labs Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Hetero Labs Limited's Dolutegravir exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Hetero Labs Limited
Full Company Profile →
46 products · $319.3M total trade · 18 categories
Dolutegravir Stats
Company Overview
Top Products by Hetero Labs Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Hetero Labs Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Dolutegravir. For current shipment-level data, contact TransData Nexus.